TY - JOUR
T1 - Beneficial effects of fetal liver tissue on fetal pancreatic transplantation
AU - Tafra, L.
AU - Berezniak, R.
AU - Dafoe, D. C.
PY - 1990/1/1
Y1 - 1990/1/1
N2 - Recently, composite grafts of hepatocytes and islets have been shown to improve the survival of hepatocytes. The possibility of a reciprocal effect of hepatocytes on islet function was investigated. Diabetic Lewis rats were isografted with (1) fetal pancreas and fetal liver (FP/FL), (2) fetal pancreas alone (FP), and (3) fetal pancreas and fetal spleen (FP/FS). Grafts were transplanted to the small bowel suberosa. All (6/6) (FP/FL recipients were cured (glucose < 250 mg/dl for > 30 days), whereas only 72% (13/18) of FP alone and 60% (3/5) of FP/FS recipients were cured. The amount of time to normoglycemia for FP/FL recipients was less (26 ± 15 days) compared with FP (50 ± 29 days) or FP/FS recipients (71 ± 40 days). Mean glucose levels at 6 weeks were 166 ± 78 mg/dl, 237 ± 97 mg/dl, and 355 ± 81 mg/dl in cured FP/FL, FP, and FP/FS recipients, respectively. Glucose tolerance test results were not significantly different from those of nondiabetic control rats. In contrast to FP alone, FP/FL recipients had well-granulated hyperplastic islets and hepatocytes on histologic examination. When new isograft recipients were treated with cyclosporine, all FP recipients remained hyperglycemic; however, 75% (6/8) of FP/FL recipients were cured. In conclusion, FL in a composite graft with FP resulted in better engraft, earlier isograft function, and protection from cyclosporine islet toxicity.
AB - Recently, composite grafts of hepatocytes and islets have been shown to improve the survival of hepatocytes. The possibility of a reciprocal effect of hepatocytes on islet function was investigated. Diabetic Lewis rats were isografted with (1) fetal pancreas and fetal liver (FP/FL), (2) fetal pancreas alone (FP), and (3) fetal pancreas and fetal spleen (FP/FS). Grafts were transplanted to the small bowel suberosa. All (6/6) (FP/FL recipients were cured (glucose < 250 mg/dl for > 30 days), whereas only 72% (13/18) of FP alone and 60% (3/5) of FP/FS recipients were cured. The amount of time to normoglycemia for FP/FL recipients was less (26 ± 15 days) compared with FP (50 ± 29 days) or FP/FS recipients (71 ± 40 days). Mean glucose levels at 6 weeks were 166 ± 78 mg/dl, 237 ± 97 mg/dl, and 355 ± 81 mg/dl in cured FP/FL, FP, and FP/FS recipients, respectively. Glucose tolerance test results were not significantly different from those of nondiabetic control rats. In contrast to FP alone, FP/FL recipients had well-granulated hyperplastic islets and hepatocytes on histologic examination. When new isograft recipients were treated with cyclosporine, all FP recipients remained hyperglycemic; however, 75% (6/8) of FP/FL recipients were cured. In conclusion, FL in a composite graft with FP resulted in better engraft, earlier isograft function, and protection from cyclosporine islet toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0025093959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025093959&partnerID=8YFLogxK
M3 - Article
C2 - 2218886
AN - SCOPUS:0025093959
SN - 0039-6060
VL - 108
SP - 734
EP - 741
JO - Surgery
JF - Surgery
IS - 4
ER -